Figure 1.

Integrated approach for the preparation of ¹⁹F‐labeled Lewis type 2 glycans by AGA and screening against lectins and enzymes. A) BBs 1–5, including BB 1 bearing the ¹⁹F reporter, were employed for the AGA of a collection ¹⁹F‐labeled Lewis type 2 antigen analogs represented following the Symbol Nomenclature For Glycans (SNFG). ^[16] B) The F‐glycans were screened against proteins, including mammalian and bacterial lectins, as well as enzymes. The enzymes were screened in the absence of donor (i.e. CMP‐Neu5Ac) to probe binding to the substrate. The binding strength was defined depending on the changes observed in the NMR after addition of the protein (right panel). Strong binding (blue) is defined as a decrease in peak intensity higher than −25 % or a chemical shift perturbation (CSP) bigger than 0.01 ppm in the ¹⁹F NMR. Weak/medium binding (light blue) is defined as a decrease in peak intensity higher than −25 % in the CPMG‐filtered ¹⁹F NMR. No binding (white) is defined as a decrease in peak intensity lower than −25 % in CPMG‐filtered ¹⁹F NMR.